Table 1 Age, predominant genetic ancestry, ABOBEC mutational signature, HPV status, TMB, MSI, and CD274 amplification between PD-L1positive and PD-L1negative uterine cervical carcinoma disease subset.
From: Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma
Patient characteristics | PD-L1 positive (n = 548) | PD-L1 negative (n = 99) | p value |
|---|---|---|---|
Age (years) | *0.589 | ||
Median | 53 | 51 | |
Mean | 53 | 52 | |
Predominant ancestry | **0.597 | ||
African | 13.3% (73) | 13.1% (13) | |
Central and South American | 15.8% (87) | 15.2% (15) | |
East Asian | 6.6% (36) | 10.1% (10) | |
European | 63.0% (346) | 60.6% (60) | |
South Asian | 1.1% (6) | 1.0% (1) | |
APOBEC mutational signature | 15.8% (87) | 2% (2) | ***<0.001 |
High-risk HPV | 77.9% (427) | 70.7% (70) | ***0.122 |
TMB (mutations/Mb) | *0.592 | ||
median | 5 | 5 | |
mean | 7.68 | 7.34 | |
≥10 | 26.3% (144) | 17.2% (17) | ***0.058 |
MSI-High | 2.2% (12) | 0% (0) | ***0.230 |
CD274 amplification | 2.4% (13) | 0% (0) | ***0.236 |
